文献速递免疫规划

无猪圆环病毒人轮状病毒疫苗液体剂型的反应原性与安全性:一项III期、观察者盲法、随机、多国研究

Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study.
PubMed 文献 · Vaccine · 2022-02-26

本研究为III期观察者盲法随机多国试验,纳入6-12周龄健康婴儿,比较液体无猪圆环病毒人轮状病毒疫苗(N=677)与冻干人轮状病毒疫苗(N=674)接种2剂后的反应原性与安全性。结果显示两组征集性一般不良事件发生率相当,严重不良事件例数分别为39例和38例,未报告死亡,两者反应原性与安全性特征相似。

要点

  • 液体无猪圆环病毒人轮状病毒疫苗与冻干人轮状病毒疫苗的反应原性和安全性特征相似。
  • 最常见征集性一般不良事件为易激惹/烦躁,液体组74.9%、冻干组72.1%。
  • 液体组39例、冻干组38例婴儿报告至少1例严重不良事件,未报告死亡。

核心结论

  • 研究表明液体无猪圆环病毒人轮状病毒疫苗与冻干人轮状病毒疫苗的反应原性和安全性特征相似。

研究设计与样本

  • III期、观察者盲法、随机、对照、多国研究,纳入6-12周龄健康婴儿。
  • 婴儿随机接受2剂液体无猪圆环病毒人轮状病毒疫苗(N=677)或冻干人轮状病毒疫苗(N=674),间隔1-2个月。
  • 征集性不良事件在每剂后记录8天,非征集性不良事件记录31天,严重不良事件从第1剂至6个月安全性随访结束。

主要发现

  • 征集性一般不良事件发生率在液体无猪圆环病毒人轮状病毒疫苗组与冻干人轮状病毒疫苗组相当,最常见为易激惹/烦躁(74.9% [95%CI: 71.4-78.1] 和72.1% [68.6-75.5])。
  • 非征集性不良事件在液体组和冻干组分别报告于29.7%(26.3-33.3)和30.6%(27.1-34.2)的婴儿。
  • 液体组39例和冻干组38例婴儿报告至少1例严重不良事件;最常见严重不良事件为上呼吸道感染(0.7%和0.9%)和尿路感染(0.9%和0.6%)。
  • 液体组1例严重不良事件(便秘)被研究者认为可能与疫苗接种存在潜在因果关系。
  • 未报告死亡。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The introduction of rotavirus vaccines in national immunization programs has decreased mortality and hospitalizations due to diarrhea. GSK's live-attenuated, human rotavirus vaccine (HRV) is a 2-dose vaccine for oral administration. Following the detection of porcine circovirus type 1 (PCV-1) in HRV, a PCV-free (no detection of PCV-1 and PCV-2 according to the detection limits of tests used) HRV was developed. The immunogenicity, reactogenicity and safety of a liquid (liq) PCV-free HRV were assessed in two prior studies. The present study aimed to generate additional reactogenicity and safety data. METHODS: This phase III, observer-blind, randomized, controlled multi-country study enrolled healthy 6-12-week-old infants. Infants were randomized to receive 2 doses of either the liq PCV-free HRV (N = 677) or the lyophilized (lyo) HRV (N = 674) 1-2 months apart. Solicited adverse events (AEs) were recorded for 8 days after each dose, unsolicited AEs for 31 days and serious AEs (SAEs) from dose 1 until the end of the 6-month safety follow-up. RESULTS: The occurrence of solicited general AEs was comparable between the liq PCV-free HRV and the lyo HRV groups, with irritability/fussiness being the most frequently reported (74.9% [95% confidence interval: 71.4-78.1] and 72.1% [68.6-75.5]). Unsolicited AEs were reported for 29.7% (26.3-33.3) and 30.6% (27.1-34.2) of infants in the liq PCV-free HRV and the lyo HRV group. A total of 39 and 38 infants reported at least one SAE, respectively. The most common SAEs were upper respiratory tract (0.7% and 0.9%) and urinary tract infections (0.9% and 0.6%). One SAE (constipation) in the liq PCV-free HRV group was considered as potentially causally related to vaccination by the investigator. No deaths were reported. CONCLUSIONS: The study showed that the reactogenicity and safety profiles of the liq PCV-free HRV and the lyo HRV are similar. CLINICALTRIALS: gov identifier: NCT0395474.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Lau YL, Fan Leung T, Sirvan Cetin B, et al. Safety and reactogenicity of a liquid formulation of human rotavirus vaccine (porcine circovirus-free): A phase III, observer-blind, randomized, multi-country study. Vaccine. 2022. PMID: 35232596. doi:10.1016/j.vaccine.2022.02.065

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。